405238-89-3

Upstream product

• 154540-17-7 (S)-(-)-4-[(tert-butyldimethylsilyloxy)methyl]-2-fluoro-2-buten-4-olide 
• 405238-67-7 1-Hydroxy-2-fluoro-4-<(tert-butyldimethylsiloxy)methyl>-2-buten-4-olide 
• 154540-16-6 (S)-(-)-2-Fluoro-4-(hydroxymethyl)-2-buten-4-olide 
• 147410-74-0 (E)/(Z)-ethyl 3-[(S)-2,2-dimethyl-(1,3)-dioxolan-4-yl]-2-fluoroacrylate 
• 405238-68-8 1-acetyl-4-[(tert-butyldimethylsilyloxy)methyl]-2-fluoro-2-buten-4-olide 
• 1005770-60-4 N-(5-methyl-2-oxo-1-trimethylsilanyl-1,2-dihydro-pyrimidin-4-yl)-benzamide 

Downstream Products

• 405238-94-0 5-methyl-1-(2,3-dideoxy-2-fluoro-β-D-glycero-pent-2-enofuranosyl)cytosine 
• 1028310-75-9 N-[1-((2R,5S)-3-Fluoro-5-hydroxymethyl-2,5-dihydro-furan-2-yl)-5-methyl-2-oxo-1,2-dihydro-pyrimidin-4-yl]-benzamide 

Relevant academic research and scientific papers

Structure-activity relationships of 2′-fluoro-2′,3′-unsaturated d-nucleosides as anti-hiv-1 agents

We studied the structure-activity relationships of a series of 2′-fluoro-2′,3′-unsaturated D-nucleosides against HIV-1 in human peripheral blood mononuclear (PBM) cells. The target compounds 10-21 and 28-33 were prepared by N-glycosylation of the acetate